Lincoln National Corp Sells 6,008 Shares of Pfizer Inc. (NYSE:PFE)

Lincoln National Corp trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 4.3% during the fourth quarter, Holdings Channel reports. The firm owned 134,971 shares of the biopharmaceutical company’s stock after selling 6,008 shares during the quarter. Lincoln National Corp’s holdings in Pfizer were worth $3,886,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares in the last quarter. GoalVest Advisory LLC raised its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Finally, Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer in the 4th quarter worth $36,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.4 %

PFE stock traded down $0.39 during trading on Tuesday, hitting $27.78. 65,400,901 shares of the company traded hands, compared to its average volume of 43,591,664. The company has a 50-day moving average of $26.90 and a 200-day moving average of $28.14. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The firm has a market capitalization of $157.28 billion, a PE ratio of -471.42, a P/E/G ratio of 1.17 and a beta of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the prior year, the firm posted $1.23 earnings per share. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.05%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $36.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.